Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval

Core Viewpoint - TD Cowen upgraded Milestone Pharmaceuticals (MIST) to Buy from Hold with a price target of $8 following the FDA approval of Cardamyst nasal spray for treating acute symptomatic episodes of paroxysmal supraventricular tachycardia in adults [1] Group 1: FDA Approval and Product Details - Cardamyst nasal spray received FDA approval for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults [1] - The product label is noted to be clean, with no market-limiting warnings or monitoring requirements [1] - Cardamyst is expected to be available in retail pharmacies in Q1 of 2026, with a wholesale acquisition cost of $1,649 [1]